ライフサイエンスコーパス: full analysis set

1 patients were enrolled and received CTT (the full analysis set).

2 least one post-baseline efficacy assessment (full analysis set).

3 , median 34.9 and 32.9 months, respectively, full analysis set).

4 iolations of the inclusion criteria (ie, the full analysis set).

5 ll patients for whom treatment was assigned (full analysis set).

6 patients who received tisagenlecleucel (the full analysis set).

7 to treat in all randomly assigned patients (full analysis set).

8 cipants with primary outcome data available (full analysis set).

9 analysis, which thus included 156 patients (full analysis set).

10 omly allocated patients with available data (full analysis set).

11 based on all randomly assigned patients (the full analysis set).

12 least one dose of study medication (modified full analysis set).

13 disease or treatment-related adverse events (full analysis set).

14 nts receiving at least one osimertinib dose (full analysis set).

15 placebo for 12 weeks (n = 117-125 per group, full analysis set).

16 4%) by ANOVA in an intent-to-treat analysis (full analysis set).

17 Safety was assessed in the full analysis set.

18 omized intervention and were included in the full analysis set.

19 dose of study drug and were included in the full analysis set.

20 ocated intervention and were included in the full analysis set.

21 nlecleucel infusion and were included in the full analysis set.

22 fulvestrant (n=73), and were included in the full analysis set.

23 resulting in 501 women being included in the full analysis set.

24 ion and compliance analyses were done in the full analysis set.

25 Efficacy analyses were performed using the full analysis set.

26 e margin of +/-3 letters, as assessed in the full analysis set.

27 W (281 newly assigned), were included in the full analysis set.

28 p, 268 in the placebo group) constituted the full analysis set.

29 er treatment group) randomly assigned in the full analysis set.

30 ients were enrolled, 67 were included in the full analysis set.

31 ale [0-3]) over weeks 49-52, assessed in the full analysis set.

32 use from week 5 to week 24, analysed in the full analysis set.

33 (arm A: n = 212; arm B: n = 209) formed the full analysis set.

34 on blinded independent central review in the full analysis set.

35 k 24 compared with baseline, assessed in the full analysis set.

36 measured on a constant load treadmill in the full analysis set.

37 t 6 months, analysed alongside safety in the full analysis set.

38 n the dose-expansion cohort, phase 2) in the full analysis set.

39 ed laboratory abnormalities, analysed in the full analysis set.

40 ete response assessment were included in the full analysis set.

41 ek 12, expressed as ratio of baseline in the full analysis set.

42 delines in the intention-to-treat population full analysis set.

43 ontrolled asthma at inclusion) comprised the full analysis set.

44 ts, and so 299 patients were included in the full analysis set.

45 1069/1095 (97.6%) patients comprised the Full Analysis Set.

46 set) and 149 patients were eligible for the full analysis set.

47 ents and 42 placebo patients analyzed in the full analysis set.

48 Efficacy analyses were done based on the full analysis set.

49 (n=1319); 2604 (98%) patients comprised the full analysis set.

50 respectively (-2.9% [-8.0% to 1.9%]), in the full analysis set.

51 aseline in HbA1c at week 24 by ANCOVA in the full analysis set.

52 n-inferiority limit of 0.4%) by ANOVA in the full analysis set.

53 s did not meet criteria for inclusion in the full analysis set.

54 at and 64 patients to placebo and formed the full analysis set.

55 608 (100%) patients were included in the full analysis set.

56 Adverse events were also assessed in the full-analysis set.

57 on, and objective response, analysed for the full-analysis set.

58 s-as-treated population, and efficacy in the full-analysis set.

59 rd care was assessed in the per protocol and full analysis sets.

60 590 patients were included in the full analysis set (120 in the placebo group, 120 in the

61 In the full analysis set, 327 (74%) patients in the lacosamide

62 the study treatment and were included in the full analysis set (332 in the nab-paclitaxel group and 3

63 In the full analysis set, 46 (3.3%) of 1406 participants at hig

64 igned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assign

65 Findings were similar in the full-analysis set (673 of 788 children in the aerosol gr

66 At 12 months in the modified full-analysis set, 86% (95% CI 79 to 91; 102 of 118 part

67 e primary endpoint in the intention-to-treat full analysis set (87 in the NBTXR3 group and 89 in the

68 iran and 75 receiving placebo) comprised the full analysis set (93 Black patients [24.7%]; 167 [44.3%

69 100 (40%) of 249 patients in the full analysis set achieved a response, with 19 (8%) achi

70 junction cancer in the 2.2-3.0 mg/kg cohort full analysis set across both the dose-escalation and do

71 c) from baseline at week 30, assessed in the full analysis set (all patients randomly allocated to tr

72 PROs were assessed in the full analysis set (all patients randomly assigned to the

73 esponse rate per Lugano 2014 criteria in the full analysis set (all patients who received >=1 dose of

74 Tumours version 1.1 and was performed on the full analysis set (all patients who received at least on

75 Responses were assessed in the full analysis set (all patients who received at least on

76 lmost clear" (PGA response), analysed in the full analysis set (all patients who were randomised and

77 outcome was progression-free survival in the full analysis set (all randomised patients) by masked ce

78 0 copies per mL) at week 54, analysed in the full analysis set (all randomly assigned participants wh

79 y and safety endpoints were evaluated in the full analysis set (all randomly assigned patients) and s

80 ll analyses were exploratory and done in the full analysis set (all randomly assigned patients, inclu

81 Analysis was done on the full-analysis set (all treated patients with measurable

82 nd the time from baseline to first IC in the full analysis set; an independent data review board conf

83 Analysis was by the full analysis set and multiplicity was controlled for wi

84 %) patients were treated and included in the full analysis set and safety analysis set (8q12 n=328, 8

85 ndary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety

86 ent central review which was assessed in the full analysis set and safety was assessed in the safety

87 in ACQ and AQLQ(S) were observed in both the full analysis set and the atopic eosinophilic subgroup.

88 Both the full analysis set and the safety analysis set included a

89 ary endpoint and safety were assessed in the full analysis set and the safety analysis set, respectiv

90 27 patients comprised the full analysis set and were deemed assessable for activit

91 s who received at least one study injection (full analysis set) and Env-specific binding antibodies i

92 ts who received at least one dose of CMG901 (full analysis set) and in all CMG901-treated patients wi

93 participants randomly assigned to treatment (full analysis set) and safety assessed in all randomly a

94 nts who were not lost to follow-up (modified full-analysis set) and in participants in the modified f

95 ohort A, 39 in cohort B, and 30 in cohort C; full analysis set), and 116 patients received at least o

96 A total of 553 patients comprised the full analysis set, and 560 patients comprised the safety

97 d; therefore, 511 women were included in the full analysis set; and in PRIMROSE 2, 535 women were enr

98 lk Test distance at week 96, analysed in the full-analysis set by means of a mixed model for repeated

99 able CNS lesion and were included in the CNS full analysis set (cFAS); 40 of 118 and 38 of 104 had >=

100 Among 425 patients in the full analysis set, CFB in HAMD-17 total score at Day 3 w

101 Outcome analyses were performed in the full analysis set comparing the zilucoplan group with th

102 The full analysis set comprised 115 patients receiving cispl

103 The full analysis set comprised 124 placebo- and 117 micafun

104 The full analysis set comprised 1385 patients (692 in the RI

105 The full analysis set comprised 344 patients (172 micafungin

106 The full analysis set comprised 78 patients from the NG101 g

107 l participants exposed to treatment, and the full analysis set comprised all randomly allocated parti

108 The PRO full analysis set comprised patients who received study

109 The safety and full analysis sets comprised 452 participants who receiv

110 35; P < 0.001) in a univariate model, on the full analysis set comprising 1029 patients.

111 The full analysis set, comprising all randomly assigned part

112 to not meeting eligibility criteria, so the full analysis set consisted of 250 patients in the delgo

113 The full analysis set consisted of 57 patients, 54 (95%) had

114 0 mg in error, so the efficacy analysis set (full analysis set) consisted of 173 in the fezolinetant

115 Analyses were done on the full analysis set, consisting of all randomised patients

116 ed relapses up to 156 weeks, assessed in the full analysis set (defined as all randomly assigned part

117 h treatment phase, which was assessed in the full analysis set, defined as all randomised patients wh

118 and ANCHOR-2; 528 participants comprised the full analysis set (depemokimab, n=272; placebo, n=256).

119 93 patients (3% of the full analysis set) died during the study, of which one d

120 icenter phase 3 trial of intention-to-treat (full analysis set), evaluable (per protocol), and safety

121 2 weeks (SVR12) was assessed in the modified full analysis set (FAS), defined as all patients excludi

122 assigned, 107 of whom were included into the full analysis set (FAS).

123 Analyses were conducted on a full analysis set (FAS; all enrolled) and modified FAS (

124 t (ie, patients that received induction) and full analysis set (FAS; ie, randomly assigned patients w

125 in CDASI-A score at week 12 assessed in the full analysis set (FAS; stage 1) and the pooled skin FAS

126 an intention-to-treat (ITT) population and a full-analysis set (FAS).

127 months, analyzed using multiple imputations (full analysis set [FAS]).

128 s were randomly assigned and included in the full analysis set for efficacy analyses (259 vs 259 vs 2

129 ceptor-positive ovarian cancer comprised the full analysis set for efficacy.

130 d maintenance study were not included in the full analysis set for the maintenance study.

131 97 (62%) patients in the full analysis set had brain metastases.

132 and safety endpoints were analysed with the full analysis set (ie, all participants randomly assigne

133 The primary analyses were done in the full analysis set (ie, all participants to whom study tr

134 50 HIV-1 RNA copies per mL at week 48 in the full analysis set (ie, all participants who received at

135 50 HIV-1 RNA copies per mL at week 48 in the full analysis set (ie, all participants who received at

136 Efficacy and safety were assessed in the full analysis set (ie, all patients who received at leas

137 and secondary endpoints were assessed in the full analysis set (ie, all randomised patients who recei

138 The primary outcome was evaluated in the full analysis set (ie, all randomly assigned participant

139 fficacy and safety analyses were done in the full analysis set (ie, all randomly assigned patients).

140 Primary analyses were done in the full analysis set (ie, all randomly assigned patients, a

141 ary endpoint and safety were assessed in the full analysis set (ie, participants who received at leas

142 combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disea

143 2023.1124 participants were included in the full analysis set in evolutionRMS1 (560 in the evobrutin

144 risk differences based on the observed data (full analysis set) in the active groups vs the placebo g

145 The full analysis set included 105 patients (80 patients wit

146 The full analysis set included 397 patients (81 in the place

147 The full analysis set included 436 participants assigned to

148 Therefore, the full analysis set included 44 patients (16 in the simvas

149 This full analysis set included all randomly assigned partici

150 hase (12-week double-blind treatment period) full analysis set included all randomly assigned patient

151 The full analysis set included patients who received at leas

152 The full-analysis set included 1081 patients (arm 1: n = 528

153 The full-analysis set included 68 women and 57 men.

154 The full analysis set includes all 34 enrolled and treated p

155 enicity and safety analyses were done on the full analysis set, including participants who, or whose

156 stigational product and were included in the full analysis set (mean [SD] age, 50 [13] years; 47% fem

157 In the full analysis set (mean age 54.5 years, 40.9% women), pa

158 251 allocated glargine were included in the full analysis set (mean age 58.9 years [SD 9.3], diabete

159 From baseline to 12 weeks in the full-analysis set, mean off-time decreased by 4.04 h (SE

160 In the full analysis set, median age was 56.0 years (IQR 47-64)

161 In the full analysis set, median PFS was significantly inferior

162 In the full analysis set, median time to the first relapse was

163 We analysed all efficacy endpoints in the full-analysis set (modified intention-to-treat analysis)

164 The full analysis set of ELEVATE UC 52 comprised 289 patient

165 We present 3-year outcomes for the full analysis set of patients who received at least one

166 Analyses were done in the full analysis set of patients who were randomly assigned

167 Analyses were on the full analysis set of patients, defined as patients who h

168 Analyses were performed on the full analysis set of patients, who underwent random allo

169 We assessed efficacy in a full-analysis set of participants with data for baseline

170 ed to receive semaglutide 1.0 mg or placebo (full analysis set), of whom 301 received at least one do

171 In the full analysis set, one patient achieved a partial respon

172 ention-to-treat safety evaluable population, full analysis set or efficacy-evaluable population, and

173 worse stomatitis by 8 weeks assessed in the full analysis set (patients who received at least one do

174 se of at least 50% (ACR50) at month 6 in the full analysis set (patients who were randomly assigned t

175 ment, and activity analyses were done in the full-analysis set (patients who received at least one do

176 ytomegalovirus infection, analysed using the full analysis set population (ie, those who received at

177 domly assigned patients were included in the full analysis set population analysis.

178 The full analysis set population included 246 patients (mean

179 The PRO full analysis set population included 366 participants i

180 Efficacy analyses were done in the full analysis set population, comprising all patients wh

181 The proportion of patients in the full analysis set predicted by the Kaplan-Meier method t

182 124 (70%) of 177 patients in the modified full analysis set receiving extended-pulsed fidaxomicin

183 ere randomized, and 162 were included in the full analysis set, receiving either aspirin plus rivarox

184 ses were by intention to treat (based on the full analysis set); safety analyses included patients ac

185 In the prespecified subgroup analysis of the full analysis set stratified by concomitant autoimmune d

186 Mortality up until day 42 in the full-analysis-set subpopulation (ITT participants with p

187 ho received at least one dose of study drug (full analysis set), SVR12 for the 8-week regimen of graz

188 , in 84 patients from cohorts A and B in the full analysis set, the confirmed objective response rate

189 For the full analysis set, the least squares mean absolute chang

190 d patients, 235 (99.6%) were included in the full analysis set; this included 116 in the tenapanor pl

191 taking carbamazepine-CR were included in the full analysis set (took at least one dose of study treat

192 0 and 12 values for each participant) in the full-analysis set using a mixed-effects model for repeat

193 The median overall survival (OS) of the full analysis set was 20.0 mo.

194 ich superiority compared with placebo in the full analysis set was first tested and then, if positive

195 The full analysis set was used for all efficacy analyses and

196 The median OS in the full-analysis set was 15.6 months (95% CI, 11.5 to 20.2)

197 rimary endpoints, assessed at week 24 in the full analysis set, were peak FEV1 response, measured wit

198 Data were analysed in the full analysis set, which comprised the 54 patients who r

199 in HbA1c after 24 weeks of treatment in the full analysis set, which consisted of all randomly assig

200 ctivity and safety analyses were done in the full analysis set, which included all participants who r

201 rogression-free survival was measured in the full analysis set, which included all patients enrolled

202 This endpoint was assessed in the full analysis set, which included all patients from the

203 defined as ypN0 or ypT0/is), assessed in the full analysis set, which included all patients who had a

204 vity and safety analyses are reported in the full analysis set, which included all patients who recei

205 ator-assessed objective response rate in the full analysis set, which included all patients who recei

206 lic blood pressure and HbA1c measured in the full analysis set, which included all patients who recei

207 ndent central review and was assessed in the full analysis set, which included all patients who signe

208 Efficacy endpoints were assessed in the full analysis set, which included all patients who were

209 Efficacy was assessed in the full analysis set, which included all randomised patient

210 Coprimary endpoints were assessed in the full analysis set, which included all randomly assigned

211 d progression-free survival, assessed in the full analysis set, which included all randomly assigned

212 ary outcome was time to first relapse in the full analysis set, which included all randomly assigned

213 Data analysis was based on the full analysis set, which is as close as possible to the

214 Overall response was analysed in the full analysis set, which was defined as all patients who

215 sis set) and in participants in the modified full-analysis set who did not deviate from the assigned

216 Analyses were done on the full analysis set with missing values imputed by last ob

217 ire at baseline and were included in the PRO full analysis set, with 376 patients treated with enfort

218 s, 123 of whom were included in the modified full analysis set, with a mean age of 11.1 years.

219 (52% [95% CI 43-60]) of 147 patients in the full analysis set, with responses that could be assessed